SB-277011 inhibits the signaling pathway between G-protein-coupled receptors (GPCRs) and G proteins. It targets 5-HT1B receptor, 5-HT1D receptor, D2 receptor, and D3 receptor.
SB-277011 can be used to research and develop therapeutic strategies for certain diseases that involve excessive activation of GPCR-G protein signaling pathways.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
